Ensign Peak Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-71,355
| Closed | -$3.11M | – | 1774 |
|
|
2023
Q3 | $3.11M | Buy |
71,355
+52,215
| +273% | +$2.27M | 0.01% | 702 |
|
|
2023
Q2 | $692K | Buy |
19,140
+3,150
| +20% | +$114K | ﹤0.01% | 1508 |
|
|
2023
Q1 | $595K | Hold |
15,990
| – | – | ﹤0.01% | 1589 |
|
|
2022
Q4 | $725K | Sell |
15,990
-76,627
| -83% | -$3.47M | ﹤0.01% | 1427 |
|
|
2022
Q3 | $6.47M | Hold |
92,617
| – | – | 0.02% | 464 |
|
|
2022
Q2 | $6.22M | Hold |
92,617
| – | – | 0.01% | 481 |
|
|
2022
Q1 | $7.62M | Buy |
92,617
+727
| +0.8% | +$59.8K | 0.02% | 485 |
|
|
2021
Q4 | $13.5M | Buy |
91,890
+14,183
| +18% | +$2.08M | 0.03% | 400 |
|
|
2021
Q3 | $13.7M | Buy |
77,707
+28,835
| +59% | +$5.1M | 0.03% | 372 |
|
|
2021
Q2 | $7.89M | Buy |
48,872
+22,135
| +83% | +$3.58M | 0.02% | 493 |
|
|
2021
Q1 | $4.58M | Buy |
26,737
+6,663
| +33% | +$1.14M | 0.01% | 663 |
|
|
2020
Q4 | $4.41M | Sell |
20,074
-11,034
| -35% | -$2.42M | 0.01% | 657 |
|
|
2020
Q3 | $5.17M | Buy |
31,108
+7,374
| +31% | +$1.22M | 0.01% | 622 |
|
|
2020
Q2 | $2.71M | Sell |
23,734
-2,798
| -11% | -$319K | 0.01% | 812 |
|
|
2020
Q1 | $2.04M | Buy |
26,532
+23,632
| +815% | +$1.82M | 0.01% | 818 |
|
|
2019
Q4 | $373K | Buy |
+2,900
| New | +$373K | ﹤0.01% | 1554 |
|